How specialty-drug prior authorization criteria separate medical necessity, step-therapy failure, contraindications, and ongoing monitoring

Specialty-drug prior authorization is rarely one question. It is a series of coverage tests, and each one asks for something different. Separating those tests helps patients, prescribers, pharmacists, and benefits teams see what the plan is asking for and where a request can fall short.

KFF reports that available prior authorization data show insurers denied at least 1 in 8 standard requests across Medicare Advantage, Medicaid managed care, and the federally facilitated ACA Marketplaces, with variation across segments. The data do not explain why any particular request was denied. They do show why complete documentation matters from the beginning.

Medical necessity starts with the patient’s condition

Medical necessity criteria usually address the diagnosis, disease severity, relevant symptoms, prior clinical findings, and the reason the requested therapy fits the member’s condition. For specialty drugs, the insurer can also ask whether the requested use matches FDA-approved labeling or another covered compendia-supported use, when the benefit design uses that framework.

This review is about clinical fit, not treatment order. A request can fail medical necessity review before the plan considers whether other drugs were tried first.

Step-therapy failure focuses on preferred options

Step therapy is a separate gate. The plan wants to know whether the member has already used a treatment that the formulary places earlier in the sequence, and what happened afterward. Documentation often needs to establish one of three paths:

  1. The prerequisite therapy was tried and did not work well enough.
  2. The prerequisite therapy caused an adverse effect or was not tolerated.
  3. The prerequisite therapy is inappropriate because of a contraindication.

The distinction matters. “Failure” does not mean the same thing as “contraindication,” and a chart note saying only that a patient “cannot take” a drug may not answer the utilization-management question the plan asked.

Contraindications explain an exception to the usual sequence

Contraindication criteria generally support an exception. The prescriber needs to document a comorbidity, interaction risk, prior serious reaction, or another clinical factor showing why a step-therapy drug should not be used. Specificity matters here. A plan can accept a clear medical reason while rejecting a general statement of preference.

Continued coverage depends on monitoring

Initial approval and renewal are often reviewed differently. Ongoing monitoring documentation addresses whether the patient is benefiting, whether safety checks were completed, and whether the prescriber is following the plan’s renewal criteria. Depending on the drug and policy, the record can include updated chart notes, lab results, imaging, symptom scores, or documentation that treatment was not interrupted in a way the policy treats as clinically significant.

Transparency matters here. As KFF Health News put it in a broader discussion of health care pricing and trust, “when you don’t know all the costs, when there’s no transparency, it’s impossible to determine if it’s a better solution or not.” The practical point applies to prior authorization criteria as well. When the standard is unclear, approvals and denials are harder to predict.

Disclaimer: This article is for general educational purposes only and is not medical advice, legal advice, or a guarantee of coverage. Coverage rules vary by plan and policy language. Patients should check plan documents and speak with their clinician, pharmacist, or insurer about a specific request or appeal.

Sources